While I await the official results of this trial, it may be an important finding. Congestive Heart Failure continues to be a huge problem in the US. If this trial is correct, eplerenone may become an important additional medication for treatment of CHF even in patients with "mild" CHF (in addition to B-blockers/ACE inhibitors/Angiotension Receptor Blockers/diuretics/nitrates/digoxin)
"Pfizer is to halt recruitment of patients to the EMPHASIS-HF trial testing its selective aldosterone inhibitor eplerenone in mild heart-failure patients because of a significant benefit of the drug."
http://feedproxy.google.com/~r/Theheartorg/~3/LvXRqu5KYJU/1083009.do
No comments:
Post a Comment